{"id":476624,"date":"2021-04-15T07:03:14","date_gmt":"2021-04-15T11:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/"},"modified":"2021-04-15T07:03:14","modified_gmt":"2021-04-15T11:03:14","slug":"finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/","title":{"rendered":"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit"},"content":{"rendered":"
\n

SOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery<\/em>\u00a0platform to develop a novel class of orally administered biological drugs,\u00a0today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat and panel discussion at the virtual Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021.<\/p>\n

A recording of the fireside chat will be available under the \u2018Investors & News<\/a>\u2019 section of the Finch website on April 22, 2021. An archived replay will be accessible for 30 days following the event.<\/p>\n

\n About Finch Therapeutics<\/strong>\n <\/p>\n

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery<\/em>\u00ae<\/sup>\u00a0platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch\u2019s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent\u00a0C. difficile<\/em>\u00a0infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn\u2019s disease, respectively.<\/p>\n

\n Media Contact:<\/strong>
\n
Gabriella Linville-Engler
media@finchtherapeutics.com<\/a><\/p>\n

Investor Contact:<\/strong>
Greg Perry
ir@finchtherapeutics.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery\u00a0platform to develop a novel class of orally administered biological drugs,\u00a0today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat and panel discussion at the virtual Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. A recording of the fireside chat will be available under the \u2018Investors & News\u2019 section of the Finch website on April 22, 2021. An archived replay will be accessible for 30 days following the event. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery\u00ae\u00a0platform to develop a novel class of orally … <\/p>\n

Continue reading “Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476624","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFinch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery\u00a0platform to develop a novel class of orally administered biological drugs,\u00a0today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat and panel discussion at the virtual Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. A recording of the fireside chat will be available under the \u2018Investors & News\u2019 section of the Finch website on April 22, 2021. An archived replay will be accessible for 30 days following the event. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery\u00ae\u00a0platform to develop a novel class of orally … Continue reading "Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T11:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit\",\"datePublished\":\"2021-04-15T11:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/\"},\"wordCount\":311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/\",\"name\":\"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=\",\"datePublished\":\"2021-04-15T11:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/","og_locale":"en_US","og_type":"article","og_title":"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk","og_description":"SOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (\u201cFinch\u201d or \u201cFinch Therapeutics\u201d) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery\u00a0platform to develop a novel class of orally administered biological drugs,\u00a0today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat and panel discussion at the virtual Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. A recording of the fireside chat will be available under the \u2018Investors & News\u2019 section of the Finch website on April 22, 2021. An archived replay will be accessible for 30 days following the event. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its\u00a0Human-First Discovery\u00ae\u00a0platform to develop a novel class of orally … Continue reading \"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T11:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit","datePublished":"2021-04-15T11:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/"},"wordCount":311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/","name":"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=","datePublished":"2021-04-15T11:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzE0MyM0MTIxNDkyIzIxOTI4ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/finch-therapeutics-to-participate-in-the-jefferies-microbiome-based-therapeutics-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Finch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476624"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476624\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}